Evotec SE (EVO) Non-Current Deffered Revenue (2020 - 2026)
Evotec SE (EVO) posted Non-Current Deffered Revenue of $154630.9 for Q1 2026, down 8.59% sequentially from $169163.5 in Q4 2025, and down 24.37% YoY from $204456.9 in Q1 2025.
Evotec SE (EVO) Non-Current Deffered Revenue (2020 - 2026) Analysis & Trends
Evotec SE has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $154630.9 in Q1 2026.
- Quarterly Non-Current Deffered Revenue fell 24.37% year-over-year to $154630.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $154630.9 (down 24.37% YoY) and the FY2025 annual result came in at $169163.5, down 99.9% from the prior year.
- Non-Current Deffered Revenue fell to $154630.9 in Q1 2026 per EVO's latest filing, from $169163.5 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $210.3 million in Q4 2022 and troughed at -$205795.8 in Q2 2022.
- A 5-year average of $45.5 million and a median of $190800.6 in 2025 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue jumped 449.18% in 2022, then tumbled 99.9% in 2025.
- Over 5 years, Non-Current Deffered Revenue stood at $210.3 million in 2022, then decreased by 20.56% to $167.1 million in 2023, then advanced by 0.21% to $167.4 million in 2024, then sank by 99.9% to $169163.5 in 2025, then fell by 8.59% to $154630.9 in 2026.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $154630.9, $169163.5, and $197969.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Evotec SE | 687.23 Mn | 686.75 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 154,630.91 |
| Dec 31, 2025 | 169,163.46 |
| Sep 30, 2025 | 197,968.96 |
| Jun 30, 2025 | 183,632.16 |
| Mar 31, 2025 | 204,456.88 |
| Dec 31, 2024 | 167.43 Mn |
| Sep 30, 2024 | 228,656.99 |
| Dec 31, 2023 | 167.08 Mn |
| Dec 31, 2022 | 210.31 Mn |
| Sep 30, 2022 | 181,458.12 |
| Jun 30, 2022 | -205,795.75 |
| Mar 31, 2022 | 126,672.65 |
| Dec 31, 2021 | 38.30 Mn |
| Sep 30, 2021 | 71,598.07 |
| Dec 31, 2020 | 26.75 Mn |